Journey Medical Corporation DERM Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Accutane | $3.31M-9.3% | $3.06M-20.9% | $2.77M-30.7% | $3.4M-40.6% | $3.66M-37.2% | |
| Emrosi | $6.25M+202% | $5M— | $4.88M— | $2.8M— | $2.07M— | |
| Foam Franchise Products Amzeeq Zilxi | $1.05M-31.2% | $1.89M-3.2% | $1.31M-37.6% | $1.14M— | $1.53M— | |
| Other Legacy | $277K-61.9% | $575K-48.6% | $701K-26.2% | $735K+1.2% | $727K-37.7% | |
| Qbrexza | $5.03M-2.6% | $5.54M-2.4% | $7.36M-2.9% | $6.95M+1.7% | $5.16M+2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Journey Medical Corporation break its business down?
- Journey Medical Corporation (DERM) reports revenue by product across 5 parts — Accutane, Emrosi, Foam Franchise Products Amzeeq Zilxi, Other Legacy and Qbrexza. Each is extracted from the segment footnotes and tracked over time.
- Where does Journey Medical Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Journey Medical Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
